Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birinapant plus Azacitidine in MDS/CMML
NCT02147873Phase 2Terminated
- Sponsor
- TetraLogic Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of birinapant in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by TetraLogic Pharmaceuticals. Started Jun 2014; status: terminated.
02
Drugs
birinapant
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02147873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02147873.